AxoGen AXGN 深 滬
等待開盤 09-23 09:30:00 美东时间
44.54
-1.390
-3.03%
華盛通- 最 高47.00
- 今 開46.17
- 成交量 133.16万股
- 最 低 44.00
- 昨 收 45.93
- 總市值 26.13亿
- 52周最高 52.91
- 市盈率 靜 --
- 換手率 2.27%
- 52周最低 15.2701
- 委 比 -91.08%
- 總股本 5867.15万
- 歷史最高 56.85
- 量 比 1.11
- 振 幅 6.53%
- 歷史最低 1.10
- 每 手 1
- 風險率 9.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多2亿美元！神经修复巨头押注这一全球首款
（来源：医疗器械创新网） 导语：Axogen以2亿美元收购BioCircuit，拿下FDA首款经510(k)许可的无缝合神经修复器械。神经修复的器械替代，正从替...
09-11 19:09
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash. The strategic acquisition integrates NerveTape, the first FDA-approved sutureless nerve repair device, into Axogen’s existing surgical solutio...
09-11 00:31
Axogen Prices $208.7M Underwritten Public Offering Of 4.91M Shares At $42.50 Per Share
Axogen, Inc. ("Axogen" or the "Company") (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an underwritten public offering of 4,910,000 shares of its common stock at a price to the...
09-10 18:06
美股大行评级 | 潜在涨幅1849.95%！Ascendiant Capital上调IGC Pharma目标价至6美元，维持"买入"评级；迪克体育、财捷遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.5美元升至6美元；Ascendiant Capital：维持Quantum Computing"买入"评级，目标价从30美元升至32美元
08-27 08:37
Truist Securities Initiates Coverage On Axogen with Buy Rating, Announces Price Target of $60
Truist Securities analyst Ravi Misra initiates coverage on Axogen (NASDAQ:AXGN) with a Buy rating and announces Price Target of $60.
08-26 21:58
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $53
HC Wainwright & Co. analyst Yi Chen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $50 to $53.
07-30 19:12
Axogen Q2 Adj. EPS $0.12 Misses $0.13 Estimate, Sales $69.731M Beat $67.098M Estimate
Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.13 by 7.69 percent. This is unchanged from the same period last year. The company reported quarterly sales of $69.731 million which beat the analyst consensus estimate of $67.098 mil...
07-29 19:06
美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
Full Transcript: Axogen Q1 2026 Earnings Call
Axogen (NASDAQ:AXGN) released first-quarter financial results and hosted an ear...
04-28 22:18
